14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $52M | -$266M | 87.3% | -519.8% | -40.6% | -32.9% | -$217M | — | $737M |
| 2024 | $64M | -$194M | 91.2% | -269.6% | -61.4% | -42.3% | -$136M | — | $392M |
| 2023 | $58M | -$81M | 91.0% | -141.0% | -88.6% | -32.0% | -$76M | — | $196M |
| 2022 | $51M | -$71M | 91.2% | -152.7% | -200.8% | -47.6% | -$63M | — | $102M |
| 2021 | $44M | -$7M | 89.9% | -179.3% | -7.4% | -3.2% | -$67M | — | $164M |
| 2020 | $17M | -$156M | 88.0% | -361.1% | -204.5% | -59.4% | -$54M | — | $228M |
| 2019 | $4M | -$86M | 45.0% | -2029.9% | 2379.4% | -109.7% | -$80M | — | $54M |
| 2018 | $2M | -$60M | 76.6% | -2970.8% | -167.2% | -82.1% | -$51M | — | $54M |
| 2017 | $2M | -$63M | 76.2% | -3220.1% | -242.4% | -114.4% | -$59M | — | $42M |
| 2016 | — | -$45M | — | — | -86.0% | -59.7% | -$36M | — | $33M |
| 2015 | — | -$40M | — | — | -44.4% | -36.0% | -$36M | — | $31M |
| 2014 | — | -$29M | — | — | -48.8% | -36.6% | — | — | $37M |
| 2013 | — | -$13M | — | — | 22.4% | -69.6% | — | — | $18M |
| 2012 | — | -$14M | — | — | 30.2% | — | — | — | $24M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $13M | -$79M | 85.1% | -609.3% | -15.1% | -11.7% | -$71M | — | $599M |
| Mar '26 | $11M | -$89M | 87.7% | -865.5% | -15.2% | -12.1% | -$71M | — | $667M |
| Dec '25 | $13M | -$65M | 88.0% | -526.5% | -9.9% | -8.0% | -$57M | — | $737M |
| Sep '25 | $15M | -$69M | 87.8% | -472.3% | -26.9% | -16.9% | -$57M | — | $345M |
| Jun '25 | $13M | -$68M | 85.6% | -502.6% | -22.2% | -15.0% | -$56M | — | $391M |
| Mar '25 | $11M | -$64M | 88.2% | -597.5% | -24.1% | -15.8% | -$47M | — | $350M |
| Dec '24 | $17M | -$48M | 92.8% | -296.1% | -15.3% | -10.6% | -$40M | — | $392M |
| Sep '24 | $15M | -$36M | 89.9% | -298.2% | -10.4% | -7.4% | -$37M | — | $427M |
| Jun '24 | $16M | -$44M | 90.8% | -265.1% | -11.6% | -8.5% | -$26M | — | $460M |
| Mar '24 | $15M | -$65M | 91.0% | -214.0% | -15.9% | -12.0% | -$34M | — | $483M |
| Dec '23 | $15M | -$29M | 90.6% | -135.5% | -32.1% | -11.6% | -$23M | — | $196M |
| Sep '23 | $15M | -$516000 | 90.9% | -127.4% | -6.6% | -0.3% | -$8M | — | $111M |
| Jun '23 | $15M | -$21M | 91.4% | -135.5% | -670.0% | -16.9% | -$22M | — | $67M |
| Mar '23 | $13M | -$30M | 90.9% | -168.6% | -312.2% | -23.6% | -$23M | — | $79M |
| Dec '22 | $14M | -$16M | 92.8% | -137.6% | -43.9% | -10.4% | -$19M | — | $102M |
| Sep '22 | $12M | -$24M | 91.0% | -180.1% | -52.3% | -15.3% | -$14M | — | $121M |
| Jun '22 | $12M | -$19M | 90.6% | -162.4% | -28.5% | -10.8% | -$11M | — | $135M |
| Mar '22 | $13M | -$13M | 90.1% | -135.2% | -15.7% | -6.7% | -$19M | — | $145M |
| Dec '21 | $12M | -$4M | 91.0% | -146.6% | -4.4% | -1.9% | -$16M | — | $164M |
| Sep '21 | $12M | $3M | 89.2% | -160.7% | 3.0% | 1.2% | -$13M | — | $179M |
How the market has priced OCUL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ocular Therapeutix, Inc's revenue has grown 24.4% per year. These are computed facts, not advice.
As of FY2025, Ocular Therapeutix, Inc reported — of total debt against $737M of cash; operating income covered interest expense -22.8×.
In FY2025, gross margin was 87.3%, operating margin -519.8%, and net margin -511.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.